^
No biomarker
Cutaneous Melanoma
ipilimumab
Sensitive: A1 - Approval
No biomarker
Cutaneous Melanoma
TC
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
trametinib
Resistant: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
albumin-bound paclitaxel
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
temozolomide
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
dacarbazine
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab + ipilimumab
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
trametinib + dabrafenib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
nivolumab
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
pembrolizumab
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
talimogene laherparepvec
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
CaT
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
paclitaxel + albumin-bound paclitaxel + dacarbazine
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
CVD
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600K
Cutaneous Melanoma
encorafenib + binimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
dabrafenib
Sensitive: A2 - Guideline
BRAF V600E
Cutaneous Melanoma
vemurafenib
Sensitive: A2 - Guideline
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive: A2 - Guideline
No biomarker
Cutaneous Melanoma
PD1 inhibitor + talimogene laherparepvec
Resistant: A2 - Guideline
No biomarker
Cutaneous Melanoma
ipilimumab + talimogene laherparepvec
Sensitive: A2 - Guideline
NTRK2 fusion
Cutaneous Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Cutaneous Melanoma
entrectinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cutaneous Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK2 fusion
Cutaneous Melanoma
larotrectinib
Sensitive: A2 - Guideline
NTRK1 fusion
Cutaneous Melanoma
larotrectinib
Sensitive: A2 - Guideline
KIT K642E
Cutaneous Melanoma
imatinib
Sensitive: A2 - Guideline
KIT L576P
Cutaneous Melanoma
imatinib
Sensitive: A2 - Guideline
NRAS mutation
Cutaneous Melanoma
binimetinib
Sensitive: A2 - Guideline
NTRK3 fusion
Cutaneous Melanoma
entrectinib
Sensitive: A2 - Guideline
KIT V559
Cutaneous Melanoma
imatinib
Sensitive: A2 - Guideline
KIT W557
Cutaneous Melanoma
imatinib
Sensitive: A2 - Guideline
TERT amplification
Cutaneous Melanoma
interferon α-2b
Sensitive: B - Late Trials
PD-L1 expression
Cutaneous Melanoma
pembrolizumab
Sensitive: B - Late Trials
BRAF V600K
Cutaneous Melanoma
trametinib
Sensitive: C1 - Off-label
BRAF V600E
Cutaneous Melanoma
trametinib
Sensitive: C1 - Off-label
NRAS mutation
Cutaneous Melanoma
AS703026
Sensitive: C2 – Inclusion Criteria
BRAF V600E
Cutaneous Melanoma
cisplatin + dacarbazine
Sensitive: C3 – Early Trials
BRAF V600E
Cutaneous Melanoma
bevacizumab
Sensitive: C3 – Early Trials
NRAS mutation
Cutaneous Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
BRAF mutation
Cutaneous Melanoma
PD1 inhibitor
Resistant: C3 – Early Trials
CXCL10 elevation
Cutaneous Melanoma
IMCgp100
Sensitive: C3 – Early Trials
JAK2 underexpression
Cutaneous Melanoma
TL-1-85
Sensitive: C3 – Early Trials
JAK2 underexpression
Cutaneous Melanoma
QL-VIII-58
Sensitive: C3 – Early Trials
JAK2 underexpression
Cutaneous Melanoma
ruxolitinib
Resistant: C3 – Early Trials
JAK2 underexpression
Cutaneous Melanoma
fedratinib
Resistant: C3 – Early Trials
JAK2 underexpression
Cutaneous Melanoma
sunitinib
Resistant: C3 – Early Trials
PCSK9 underexpression
Cutaneous Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
ACSL4 overexpression
Cutaneous Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
FSIP2 mutation
Cutaneous Melanoma
Immunotherapy
Sensitive: C3 – Early Trials
KIT mutation
Cutaneous Melanoma
PD1 inhibitor
Sensitive: C3 – Early Trials
BRAF mutation
Cutaneous Melanoma
BRAF inhibitor
Resistant: C4 – Case Studies
BRAF mutation
Cutaneous Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive: C4 – Case Studies
HER-2 amplification
Cutaneous Melanoma
ado-trastuzumab emtansine
Sensitive: C4 – Case Studies
GOLGA4-RAF1 fusion
Cutaneous Melanoma
MEK inhibitor
Sensitive: C4 – Case Studies
PRKCH-SPTB fusion
Cutaneous Melanoma
IDE196
Sensitive: D – Preclinical
PRKCH fusion
Cutaneous Melanoma
IDE196
Sensitive: D – Preclinical
HIF1A-PRKCH fusion
Cutaneous Melanoma
IDE196
Resistant: D – Preclinical
PRKCH-VWA2 fusion
Cutaneous Melanoma
IDE196
Sensitive: D – Preclinical
BRAF V600E
Cutaneous Melanoma
JQ-1
Sensitive: D – Preclinical